ReviewBlood cancer journal2023
Multiple myeloma with acute light chain cast nephropathy.
Review in Blood cancer journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed.
- Optimizing lenalidomide therapy in renal impairment: analysis of renal response in the prospective REMNANT study in transplant-eligible newly diagnosed multiple myeloma.Blood cancer journal · 2025Trial
- Extracorporeal Free-Light-Chain Removal in Myeloma Cast Nephropathy: Plasma Exchange and Hemodialysis Strategies in the Era of Effective Antimyeloma Therapy.Journal of clinical medicine · 2026Review
- Maintenance therapy and improved relapse-free survival in patients with monoclonal gammopathy of renal significance.Blood advances · 2026Article
- Pathological diagnosis and differential considerations of renal diseases with organized deposits under an electron microscope: key points in diagnosis.Clinical and experimental nephrology · 2026Review
- Development and temporal validation of a machine learning-based model for predicting renal impairment in multiple myeloma: a single-center retrospective cohort study.BMC medical informatics and decision making · 2026Article
- Biclonal gammopathy with coexistent proximal tubulopathy and cast nephropathy in multiple myeloma: a rare case report.BMC nephrology · 2026Article
- Use of High- and Medium-Cut-off Membrane Hemodialysis for Removal of Free Light Chains in Patients with Multiple Myeloma-A Single-Center Experience.Journal of clinical medicine · 2026Article
- Cast nephropathy in the ICU: Early recognition and extracorporeal strategies to improve outcomes.Journal of intensive medicine · 2026Review
- Genomic profiling enables personalized strategies to overcome drug resistance in multiple myeloma.Discover oncology · 2026Review
- The Role of Therapeutic Plasma Exchange in the Management of Myeloma-Related Cast Nephropathy: A 10-Year Real-World Cohort Study.Journal of clinical medicine · 2026Article
- Neutrophils in Kidney Disease: Linking Neutrophil Function and Microenvironment to Therapeutic Targets.Journal of inflammation research · 2026Review
- Collapsing Glomerulopathy in a Patient With Malaria and Multiple Myeloma: A Case Report.Case reports in medicine · 2026Article
- Clinical predictors of monoclonal gammopathy of renal significance: a multicenter study in Japan.Clinical and experimental nephrology · 2026Article
- An Unusual Cause of Cast Nephropathy in a Patient Presenting With Hypercalcemia and Renal Failure: A Case Report.Cureus · 2026Article
- Parameters Associated With Renal Recovery and Survival in Myeloma Patients With Acute Renal Failure to Cast Nephropathy.American journal of hematology · 2026Article
- Correlation between serum lactate dehydrogenase, βPakistan journal of medical sciences · 2026Article
- Predictive value of endothelial activation and stress index for acute kidney injury in hospitalized patients with multiple myeloma.American journal of translational research · 2026Article
- Kinetics of Serum-Free Light Chain Removal by High-Cutoff Hemodialysis in Patients with Multiple Myeloma and Acute Renal Failure.Medicina (Kaunas, Lithuania) · 2025Article
- Acute kidney injury: pathogenesis and therapeutic interventions.Molecular biomedicine · 2025Review
- Machine Learning for Monoclonal Gammopathies of Renal Significance Risk Stratification Using Clinical and Pathology Data.Kidney international reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Light chain cast nephropathy (LCCN) is a leading cause of acute kidney injury (AKI) in patients with multiple myeloma (MM) and is now defined as a myeloma defining event. While the long-term prognosis has improved with novel agents, short-term mortality remains significantly higher in patients with LCCN especially if the renal failure is not reversed. Recovery of renal function requires a rapid and significant reduction of the involved serum free light chain. Therefore, proper treatment of these patients is of the utmost importance. In this paper, we provide an algorithm for treatment of MM patients who present with biopsy-proven LCCN or in those where other causes of AKI have been ruled out. The algorithm is based on data from randomized trial whenever possible. When trial data is not available, our recommendations is based on non-randomized data and expert opinions on best practices. We recommend that all patients should enroll in a clinical trial if available prior to resorting to the treatment algorithm we outlined.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.